PMID- 16273638
OWN - NLM
STAT- MEDLINE
DCOM- 20060227
LR  - 20190430
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 11
IP  - 39
DP  - 2005 Oct 21
TI  - Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
PG  - 6125-9
AB  - AIM: To determine the role of Fas/Fas ligand (FasL) in the immune escape of colon 
      cancer cells. METHODS: Immunohistochemistry was used to observe the expression of 
      Fas and FasL in the tissues of colon cancer patients. In situ hybridization was 
      used to detect the localization of FasL mRNA expression in cancer tissues. 
      Terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) 
      assay and CD45 staining were performed to detect the apoptosis of 
      tumor-infiltrating lymphocytes (TILs). Co-culture assays of colon cancer cells 
      (SW480) and Jurkat cells (Fas-sensitive cells) were performed to observe the 
      counterattack of colon cancer cells to lymphocytes. RESULTS: Of 53 cases of colon 
      carcinomas, 23 cases (43.4%) expressed Fas which was significantly lower as 
      compared to the normal colonic mucosa (73.3%, P<0.01), and 45 cases (84.9%) of 
      colon carcinomas expressed FasL, whereas only two cases (3.75%) in normal mucosa 
      expressed FasL. FasL expression in the colon cancer cells was found to be 
      associated with increased cell death of TILs. The apoptotic rate of TIL in the 
      FasL-positive staining regions of tumor cells was significantly higher than that 
      in the FasL-negative staining region (54.84+/-2.79% vs 25.73+/-1.98%, P<0.01). 
      The co-culture of SW480 cells and Jurkat cells confirmed the function of FasL on 
      the SW480 cells. The apoptotic rates of Jurkat cells were found to be related 
      with the amount of SW480 cells. CONCLUSION: Colon cancer cells can escape the 
      immune surveillance and killing via decreasing Fas expression, and can 
      counterattack the immune system via increasing FasL expression. Fas/FasL can 
      serve as potential targets for effective antitumor therapy.
FAU - Zhu, Qiang
AU  - Zhu Q
AD  - Department of Gastroenterology, Shandong Provincial Hospital, Jing 5 Wei 7 Road, 
      324#, Jinan 250021, Shandong Province, China. zhuqiang@medmail.com.cn
FAU - Liu, Ji-Yong
AU  - Liu JY
FAU - Xu, Hong-Wei
AU  - Xu HW
FAU - Yang, Chong-Mei
AU  - Yang CM
FAU - Zhang, An-Zhong
AU  - Zhang AZ
FAU - Cui, Yi
AU  - Cui Y
FAU - Wang, Hong-Bo
AU  - Wang HB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (FASLG protein, human)
RN  - 0 (Fas Ligand Protein)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Tumor Necrosis Factors)
RN  - 0 (fas Receptor)
SB  - IM
MH  - Apoptosis/immunology
MH  - Cell Survival
MH  - Coculture Techniques
MH  - Colorectal Neoplasms/*immunology/*pathology
MH  - Fas Ligand Protein
MH  - Humans
MH  - Jurkat Cells
MH  - Membrane Glycoproteins/genetics/*immunology
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factors/genetics/*immunology
MH  - fas Receptor/genetics/*immunology
PMC - PMC4436628
EDAT- 2005/11/08 09:00
MHDA- 2006/02/28 09:00
PMCR- 2005/10/21
CRDT- 2005/11/08 09:00
PHST- 2005/11/08 09:00 [pubmed]
PHST- 2006/02/28 09:00 [medline]
PHST- 2005/11/08 09:00 [entrez]
PHST- 2005/10/21 00:00 [pmc-release]
AID - 10.3748/wjg.v11.i39.6125 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2005 Oct 21;11(39):6125-9. doi: 10.3748/wjg.v11.i39.6125.